Welcome to our dedicated page for Y-Mabs Therapeutics SEC filings (Ticker: YMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Y-mAbs Therapeutics, Inc. filings document the company’s biopharmaceutical business, common stock, governance and completed transition from Nasdaq-listed issuer to deregistered reporting status. Recent 8-K reports cover operating results, material agreements, shareholder votes and completion of the merger process.
Form 25 records removal of the company’s common stock from Nasdaq listing and registration under Section 12(b) of the Exchange Act. Form 15 records termination of Section 12(g) registration and suspension of reporting duties under Sections 13 and 15(d), with the filing identifying one holder of record as of the notice date.
Transaction overview: Y-mAbs Therapeutics, Inc. entered into a Merger Agreement dated August 4, 2025 with Perseus BidCo US, Inc. (Parent), Yosemite Merger Sub, Inc. (Purchaser) and Stark International Lux. Purchaser will commence a cash Tender Offer of $8.60 per Share for all outstanding common stock, without interest and subject to applicable withholding taxes. If successful, the Tender Offer will be followed by a merger under Section 251(h) of the Delaware General Corporation Law, with the Company surviving the Merger.
Communications included: This Schedule 14D-9 consists of communications dated August 5, 2025, incorporated as Exhibits 99.1–99.6: a joint press release, an employee email, an investor/analyst letter, a patient and advocacy organization letter, a vendor/supplier letter, and a LinkedIn post.